Protocol No.: D702GC00001

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)
Principal Investigator
Bhasin, Pooja Gogia
Phase
III
Age Group
Adult
Applicable Disease Site
Lung Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Rachel Harper
Clinical Research Specialist
Phone: +1 304-293-6066

View on ClinicalTrials.gov